Management and outcome of bilateral testicular germ cell tumors: Twenty-five year experience in Munich

Authors

  • Dr Marcus Hentrich Department of Medical Oncology, Munich Harlaching Hospital, Sanatoriumsplatz 2, 81545, Munich, Germany
  • Norbert Weber Oncology Practice, Sendlinger Straße 37, 80331, Munich, Germany
  • Thorsten Bergsdorf Department of Urology, Munich Harlaching Hospital, Sanatoriumsplatz 2, 81545, Munich, Germany
  • Bernhard Liedl Department of Urology, University Hospital Großhadern, Marchioninistraße 15, 81377, Munich, Germany
  • Reiner Hartenstein Department of Medical Oncology, Munich Harlaching Hospital, Sanatoriumsplatz 2, 81545, Munich, Germany
  • Arthur Gerl Oncology Practice, Sendlinger Straße 37, 80331, Munich, Germany; Department of Internal Medicine III, University Hospital Großhadern, Marchioninistraße 15, 81377, Munich, Germany

DOI:

https://doi.org/10.1080/02841860510029923

Abstract

We analyzed characteristics, therapy and outcome of patients with bilateral testicular germ cell tumor (TGCT) at our institutions. Among 1 180 TGCT patients diagnosed and/or treated between 1979 and 2003, 47 (4.0%) developed a second TGCT. Nine of 14 patients (64%) with synchronous TGCT are alive with no evidence of disease (NED) at a median follow-up of 37 months. Thirty-three patients had a metachronous bilateral TGCT. Median time to the 2nd TGCT was 71 months. At diagnosis of 2nd TGCT 30 patients had stage I, 1 had stage II and 2 had stage III disease. Thirty-two of 33 patients are alive with NED at a median follow up of 41 months. No patient died from second TGCT. As a review of the literature confirms our data we do not recommend a routine biopsy of the contralateral testicle for early detection of testicular intraepithelial neoplasia (TIN).

Downloads

Download data is not yet available.

Downloads

Published

2005-01-01

How to Cite

Hentrich, D. M. ., Weber, N. ., Bergsdorf, T. ., Liedl, B. ., Hartenstein, R. ., & Gerl, A. . (2005). Management and outcome of bilateral testicular germ cell tumors: Twenty-five year experience in Munich. Acta Oncologica, 44(6), 529–536. https://doi.org/10.1080/02841860510029923